These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study. Farina C; Wagenpfeil S; Hohlfeld R J Neurol; 2002 Nov; 249(11):1587-92. PubMed ID: 12420101 [TBL] [Abstract][Full Text] [Related]
4. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. Putheti P; Soderstrom M; Link H; Huang YM J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106 [TBL] [Abstract][Full Text] [Related]
5. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients. Jansson A; Ernerudh J; Kvarnström M; Ekerfelt C; Vrethem M Mult Scler; 2003 Oct; 9(5):440-5. PubMed ID: 14582766 [TBL] [Abstract][Full Text] [Related]
6. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. Oreja-Guevara C; Ramos-Cejudo J; Aroeira LS; Chamorro B; Diez-Tejedor E BMC Neurol; 2012 Sep; 12():95. PubMed ID: 22989378 [TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Chen M; Gran B; Costello K; Johnson K; Martin R; Dhib-Jalbut S Mult Scler; 2001 Aug; 7(4):209-19. PubMed ID: 11548979 [TBL] [Abstract][Full Text] [Related]
8. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients. Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047 [TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta. Hussien Y; Sanna A; Söderström M; Link H; Huang YM Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948 [TBL] [Abstract][Full Text] [Related]
11. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Ragheb S; Abramczyk S; Lisak D; Lisak R Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193 [TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Sanna A; Fois ML; Arru G; Huang YM; Link H; Pugliatti M; Rosati G; Sotgiu S Clin Exp Immunol; 2006 Feb; 143(2):357-62. PubMed ID: 16412061 [TBL] [Abstract][Full Text] [Related]
14. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. Kim HJ; Ifergan I; Antel JP; Seguin R; Duddy M; Lapierre Y; Jalili F; Bar-Or A J Immunol; 2004 Jun; 172(11):7144-53. PubMed ID: 15153538 [TBL] [Abstract][Full Text] [Related]
15. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762 [TBL] [Abstract][Full Text] [Related]
16. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Tumani H; Kassubek J; Hijazi M; Lehmensiek V; Unrath A; Süssmuth S; Lauda F; Kapfer T; Fang L; Senel M; Brettschneider J Eur Neurol; 2011; 65(3):164-9. PubMed ID: 21372576 [TBL] [Abstract][Full Text] [Related]
17. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969 [TBL] [Abstract][Full Text] [Related]
18. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988 [TBL] [Abstract][Full Text] [Related]
19. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Yong VW Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849 [TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate in multiple sclerosis: a review. Ruggieri M; Avolio C; Livrea P; Trojano M CNS Drug Rev; 2007; 13(2):178-91. PubMed ID: 17627671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]